Bobby Liaw, MD

Clinical Focus

• Adrenal Gland Tumors
• Bladder Cancer
• Genitourinary Malignancies
• Kidney Cancer
• Prostate Cancer
• Renal Cancer
• Sarcomas
• Sarcomas, Soft-Tissue
• Testicular Tumors

• Adrenal Gland Tumors
• Bladder Cancer
• Genitourinary Malignancies
• Kidney Cancer
• Prostate Cancer
• Renal Cancer
• Sarcomas
• Sarcomas, Soft-Tissue
• Testicular Tumors

Research

Locations

The Blavatnik Family – Chelsea Medical Center

325 West 15th Street, 1st Floor, (between 8th and 9th Avenues), New York, NY, 10011

212-604-6010

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:6

Article:6

Review Article:9

Letter:1

Chapter:1

Recent Artifacts

• The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
• Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer
• First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis
• Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database
• Rare case of metastatic liposarcoma to the thyroid gland and a review of the literature of metastatic sarcomas to the thyroid
• Does androgen deprivation therapy protect against severe complications from COVID-19?
• Renal cancer
• The role of ketoconazole in current prostate cancer care
• Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: Evidence to date
• Management of Atypical Renal Cell Carcinomas

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Liaw did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.